<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02828241</url>
  </required_header>
  <id_info>
    <org_study_id>DFD04-CD-002</org_study_id>
    <nct_id>NCT02828241</nct_id>
  </id_info>
  <brief_title>A Study to Assess the Efficacy, Safety and Tolerability of DFD-04</brief_title>
  <official_title>A Multi-center, Randomized, Double-Blind, Parallel-group, Placebo-Controlled Study to Assess the Efficacy, Safety and Tolerability of DFD-04 (Itraconazole) Ointment, 5% in Patients With Inflammatory Lesions of Rosacea Over 12 Weeks</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Dr. Reddy's Laboratories Limited</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Dr. Reddy's Laboratories Limited</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this exploratory study is to assess the efficacy, safety and tolerability of
      DFD-04 Ointment for topical treatment of rosacea over 12 weeks of treatment.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Subjects with mild to moderate papulopustular rosacea (Investigator's Global Assessment [IGA]
      grade 2-3), a Clinician's Erythema Assessment (CEA) score of 2-3 and 6-30 inflammatory
      lesions (papules and pustules) were randomized to treatment with DFD-04 ointment or Vehicle
      ointment in a ratio of 2:1.

      During the 12-week treatment period subjects used the IMP twice daily with approximately 12
      hours between applications. Subjects were instructed to treat affected skin in a defined
      treatment area on the face.

      The investigator assessed efficacy by using an IGA 5-point scale and CEA 4-point scale and by
      counting the number of inflammatory lesions on the face at Baseline (Day 1) and Weeks 4, 8
      and 12 (End of Treatment [EoT], defined as complete clearance of inflammatory lesions or Week
      12, whichever was earlier). Furthermore, a non-invasive biomarker assessment was done by
      using a Transdermal Analysis Patch (TAP) at Baseline (Day 1) and Weeks 4 and 12.

      Safety assessments included investigator's assessment of application site reactions at
      Baseline (Day 1) and Weeks 4, 8, and 12 for all treated areas.

      Other safety assessments included vital signs (blood pressure [BP] and pulse rate) and urine
      pregnancy tests (UPTs) (only for females), clinical laboratory parameters (serum and urine),
      extent of exposure, and Adverse Events.

      In addition, pharmacokinetic (PK) analysis was performed to evaluate the systemic exposures
      of itraconazole and its active metabolite, hydroxyl-itraconazole, with blood samples drawn
      from the first 12 subjects at various pre-specified timepoints.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">July 2016</start_date>
  <completion_date type="Actual">November 2017</completion_date>
  <primary_completion_date type="Actual">January 2017</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Triple (Participant, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Change in Inflammatory Lesion Counts</measure>
    <time_frame>At the end of study (12 weeks)</time_frame>
    <description>Mean change from Baseline in the inflammatory lesion count at the End of Treatment. A lower score at the end of the study compared to Baseline is considered a better outcome.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Number of Subjects With Investigator's Global Assessment (IGA) Success</measure>
    <time_frame>At the end of study (12 weeks)</time_frame>
    <description>Number of subjects with treatment success based on Investigator's Global Assessment (IGA) score at the End of Treatment, defined as an IGA score of 0 (clear) or 1 (almost clear) with composite grade change from Baseline of at least 2 points.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Number of Subjects With Treatment Success by Clinician's Erythema Assessment (CEA) Scale</measure>
    <time_frame>At end of study (12 weeks)</time_frame>
    <description>Number of subjects with Treatment Success defined as a score of 0 or 1 and a 2 grade improvement on the CEA scale from Baseline to 12 weeks.</description>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">61</enrollment>
  <condition>Rosacea</condition>
  <arm_group>
    <arm_group_label>DFD-04 Ointment</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>DFD-04 (Itraconazole) Ointment</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo Ointment</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Placebo Ointment</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>DFD-04 Ointment</intervention_name>
    <arm_group_label>DFD-04 Ointment</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Placebo Ointment</intervention_name>
    <arm_group_label>Placebo Ointment</arm_group_label>
    <other_name>Placebo</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Subjects must be able to understand the requirements of the study and be willing to
             give written informed consent.

          2. Subjects must be willing to provide authorization to use protected health information.

          3. Subjects, any gender or race, must be in good general health as determined by the
             Investigator

          4. Subjects must have a clinical diagnosis of papulopustular rosacea, Investigator's
             Global Assessment (IGA) grade 2 - 3.

          5. Subjects must have 6 - 30 inflammatory lesions (papules and pustules) of rosacea over
             the face.

          6. Subjects must have a Clinician`s Erythema Assessment (CEA) score of 2 - 3.

          7. Subjects must have no more than 2 nodules.

          8. Subjects must agree to only use the study products and to not use any other treatment
             for rosacea (prescription or over the counter) or any other skin care or cosmetics
             product (make-up etc.) on the facial skin of the treatment area during the course of
             the study.

          9. Subjects must be free of any systemic or dermatologic disorder, which in the opinion
             of the Investigator, will interfere with the study results.

         10. Females have a negative urine pregnancy test at the Screening and Baseline Visit.

         11. Females must either be postmenopausal with no menses for at least 12 months or
             surgically sterile (hysterectomy or tubal ligation) or agree to use a reliable method
             of contraception with a failure rate of less than 1 percent per year when used
             consistently and correctly.

         12. Subject must be in good general health as determined by the investigator and supported
             by the medical history and normal or not clinically significant abnormal vital signs
             (blood pressure and pulse).

         13. Subject is physically able to apply study product to all affected areas.

        Exclusion Criteria:

          1. Females who are pregnant or nursing or planning to become pregnant during the study.

          2. Subjects who have been treated for rosacea within the 30 days prior to the Baseline
             Visit.

          3. Subjects who have been treated with systemic retinoids within 6 months prior to the
             Baseline visit.

          4. Subjects who have participated in a trial involving any investigational product in the
             30 days prior to the Baseline Visit.

          5. Subjects with any disease or medical condition that would interfere with the study or
             place the subject at undue risk especially cardiovascular diseases, reduced lung
             function (including asthma), renal dysfunction or liver dysfunction.

          6. Subjects who have been treated within 30 days prior to baseline visit with
             methadone,disopyramide, dofetilide, dronedarone, quinidine, ergot alkaloids (such as
             dihydroergotamine, ergometrine (ergonovine), ergotamine, methylergometrine
             (methylergonovine)), irinotecan, lurasidone, oral midazolam, pimozide, triazolam,
             felodipine, nisoldipine, ranolazine, eplerenone, cisapride, lovastatin, simvastatin,
             ticagrelor, terfenadine, astemizole, mizolastine, eletriptan, as well as lovastatin,
             simvastatin and atorvastatin and, in subjects with varying degrees of renal or hepatic
             impairment, colchicine, fesoterodine, telithromycin and solifenacin.

          7. Subjects who use or have used systemic steroids within the 30 days prior to the
             Baseline Visit or any other immunosuppressive medication.

          8. Subjects positive for human immunodeficiency virus (HIV), hepatitis B and hepatitis
             C-test at screening.

          9. Subjects who are unable to comply with study requirements.

         10. Subjects with other skin diseases that may confound the evaluation of rosacea.

         11. History of organ transplant requiring immunosuppression, HIV, or other immune
             compromised state.

         12. Subject who in the opinion of the investigator or physician performing the initial
             examination the subject should not participate in the trial, e.g. due to probable
             noncompliance or inability to understand the trial and give adequately informed
             consent

         13. Subject with close affiliation with the investigator (e.g. a close relative) or
             persons working at the respective trial sites or subject who are an employee of
             sponsor.

         14. Subject institutionalized because of legal or regulatory order.

         15. History of drug or alcohol abuse in the last year.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>64 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Srinivas R Sidgiddi, MD</last_name>
    <role>Study Director</role>
    <affiliation>Dr. Reddy's Laboratories Inc.</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Site 201</name>
      <address>
        <city>Berlin</city>
        <zip>10117</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site 208</name>
      <address>
        <city>Berlin</city>
        <zip>10783</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site 202</name>
      <address>
        <city>Bochum</city>
        <zip>44803</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site 205</name>
      <address>
        <city>Hamburg</city>
        <zip>22391</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site 203</name>
      <address>
        <city>Mahlow</city>
        <zip>15831</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site 204</name>
      <address>
        <city>Munster</city>
        <zip>48179</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site 207</name>
      <address>
        <city>Potsdam</city>
        <zip>14467</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site 206</name>
      <address>
        <city>Wiesbaden</city>
        <zip>65199</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Germany</country>
  </location_countries>
  <verification_date>January 2019</verification_date>
  <study_first_submitted>July 7, 2016</study_first_submitted>
  <study_first_submitted_qc>July 8, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">July 11, 2016</study_first_posted>
  <results_first_submitted>July 29, 2018</results_first_submitted>
  <results_first_submitted_qc>January 17, 2019</results_first_submitted_qc>
  <results_first_posted type="Actual">January 23, 2019</results_first_posted>
  <last_update_submitted>January 17, 2019</last_update_submitted>
  <last_update_submitted_qc>January 17, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">January 23, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Rosacea</mesh_term>
  </condition_browse>

  <clinical_results>

    <participant_flow>
      <recruitment_details>Subjects were randomized to either DFD-04 Ointment or Placebo Ointment in a ratio of 2:1</recruitment_details>
      <group_list>
        <group group_id="P1">
          <title>DFD-04 Ointment</title>
          <description>DFD-04 (Itraconazole) Ointment applied over the affected areas on the face twice daily with approximately 12 hours between applications.</description>
        </group>
        <group group_id="P2">
          <title>Placebo Ointment</title>
          <description>Placebo Ointment applied over the affected areas on the face twice daily with approximately 12 hours between applications.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="38"/>
                <participants group_id="P2" count="23"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="30"/>
                <participants group_id="P2" count="21"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="8"/>
                <participants group_id="P2" count="2"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Adverse Event</title>
              <participants_list>
                <participants group_id="P1" count="7"/>
                <participants group_id="P2" count="2"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Protocol Violation</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>DFD-04 Ointment</title>
          <description>DFD-04 (Itraconazole) Ointment</description>
        </group>
        <group group_id="B2">
          <title>Placebo Ointment</title>
          <description>Placebo Ointment
t</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="38"/>
            <count group_id="B2" value="23"/>
            <count group_id="B3" value="61"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="50.4" spread="8.1"/>
                    <measurement group_id="B2" value="44.3" spread="10.2"/>
                    <measurement group_id="B3" value="48.1" spread="9.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="25"/>
                    <measurement group_id="B2" value="18"/>
                    <measurement group_id="B3" value="43"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="13"/>
                    <measurement group_id="B2" value="5"/>
                    <measurement group_id="B3" value="18"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race (NIH/OMB)</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>American Indian or Alaska Native</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Asian</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Native Hawaiian or Other Pacific Islander</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Black or African American</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>White</title>
                  <measurement_list>
                    <measurement group_id="B1" value="38"/>
                    <measurement group_id="B2" value="23"/>
                    <measurement group_id="B3" value="61"/>
                  </measurement_list>
                </category>
                <category>
                  <title>More than one race</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown or Not Reported</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Germany</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="38"/>
                    <measurement group_id="B2" value="23"/>
                    <measurement group_id="B3" value="61"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Change in Inflammatory Lesion Counts</title>
        <description>Mean change from Baseline in the inflammatory lesion count at the End of Treatment. A lower score at the end of the study compared to Baseline is considered a better outcome.</description>
        <time_frame>At the end of study (12 weeks)</time_frame>
        <population>Intent to Treat (ITT)</population>
        <group_list>
          <group group_id="O1">
            <title>DFD-04 Ointment</title>
            <description>DFD-04 (Itraconazole) Ointment</description>
          </group>
          <group group_id="O2">
            <title>Placebo Ointment</title>
            <description>Placebo Ointment
t</description>
          </group>
        </group_list>
        <measure>
          <title>Change in Inflammatory Lesion Counts</title>
          <description>Mean change from Baseline in the inflammatory lesion count at the End of Treatment. A lower score at the end of the study compared to Baseline is considered a better outcome.</description>
          <population>Intent to Treat (ITT)</population>
          <units>Number of lesions</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="38"/>
                <count group_id="O2" value="23"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-1.4" spread="13.8"/>
                    <measurement group_id="O2" value="2.9" spread="17.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Number of Subjects With Investigator's Global Assessment (IGA) Success</title>
        <description>Number of subjects with treatment success based on Investigator's Global Assessment (IGA) score at the End of Treatment, defined as an IGA score of 0 (clear) or 1 (almost clear) with composite grade change from Baseline of at least 2 points.</description>
        <time_frame>At the end of study (12 weeks)</time_frame>
        <population>Intent to Treat (ITT) population</population>
        <group_list>
          <group group_id="O1">
            <title>DFD-04 Ointment</title>
            <description>DFD-04 (Itraconazole) Ointment</description>
          </group>
          <group group_id="O2">
            <title>Placebo Ointment</title>
            <description>Placebo Ointment</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Subjects With Investigator's Global Assessment (IGA) Success</title>
          <description>Number of subjects with treatment success based on Investigator's Global Assessment (IGA) score at the End of Treatment, defined as an IGA score of 0 (clear) or 1 (almost clear) with composite grade change from Baseline of at least 2 points.</description>
          <population>Intent to Treat (ITT) population</population>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="38"/>
                <count group_id="O2" value="23"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3"/>
                    <measurement group_id="O2" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Number of Subjects With Treatment Success by Clinician's Erythema Assessment (CEA) Scale</title>
        <description>Number of subjects with Treatment Success defined as a score of 0 or 1 and a 2 grade improvement on the CEA scale from Baseline to 12 weeks.</description>
        <time_frame>At end of study (12 weeks)</time_frame>
        <population>ITT population</population>
        <group_list>
          <group group_id="O1">
            <title>DFD-04 Ointment</title>
            <description>DFD-04 (Itraconazole) Ointment</description>
          </group>
          <group group_id="O2">
            <title>Placebo Ointment</title>
            <description>Placebo Ointment
t</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Subjects With Treatment Success by Clinician's Erythema Assessment (CEA) Scale</title>
          <description>Number of subjects with Treatment Success defined as a score of 0 or 1 and a 2 grade improvement on the CEA scale from Baseline to 12 weeks.</description>
          <population>ITT population</population>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="38"/>
                <count group_id="O2" value="23"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2"/>
                    <measurement group_id="O2" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>From start of treatment until the end of study visit at 12 weeks.</time_frame>
      <group_list>
        <group group_id="E1">
          <title>DFD-04 Ointment</title>
          <description>DFD-04 (Itraconazole) Ointment</description>
        </group>
        <group group_id="E2">
          <title>Placebo Ointment</title>
          <description>Placebo Ointment
t</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, all-cause mortality</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="38"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="23"/>
              </event>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="38"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="23"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <default_vocab>MedDRA (19.0)</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="37" subjects_at_risk="38"/>
                <counts group_id="E2" subjects_affected="19" subjects_at_risk="23"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Any Gastrointestinal Disorder</sub_title>
                <counts group_id="E1" events="7" subjects_affected="4" subjects_at_risk="38"/>
                <counts group_id="E2" events="6" subjects_affected="3" subjects_at_risk="23"/>
              </event>
              <event>
                <sub_title>Toothache</sub_title>
                <counts group_id="E1" events="4" subjects_affected="2" subjects_at_risk="38"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="23"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Any General Disorder and Administrative Site Condition</sub_title>
                <counts group_id="E1" events="127" subjects_affected="29" subjects_at_risk="38"/>
                <counts group_id="E2" events="36" subjects_affected="13" subjects_at_risk="23"/>
              </event>
              <event>
                <sub_title>Application Site Dryness</sub_title>
                <counts group_id="E1" events="7" subjects_affected="7" subjects_at_risk="38"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="23"/>
              </event>
              <event>
                <sub_title>Application Site Erythema</sub_title>
                <counts group_id="E1" events="13" subjects_affected="10" subjects_at_risk="38"/>
                <counts group_id="E2" events="4" subjects_affected="4" subjects_at_risk="23"/>
              </event>
              <event>
                <sub_title>Application Site Exfoliation</sub_title>
                <counts group_id="E1" events="5" subjects_affected="5" subjects_at_risk="38"/>
                <counts group_id="E2" events="4" subjects_affected="4" subjects_at_risk="23"/>
              </event>
              <event>
                <sub_title>Application Site Pain</sub_title>
                <counts group_id="E1" events="46" subjects_affected="22" subjects_at_risk="38"/>
                <counts group_id="E2" events="13" subjects_affected="7" subjects_at_risk="23"/>
              </event>
              <event>
                <sub_title>Application Site Pruritus</sub_title>
                <counts group_id="E1" events="42" subjects_affected="21" subjects_at_risk="38"/>
                <counts group_id="E2" events="9" subjects_affected="9" subjects_at_risk="23"/>
              </event>
              <event>
                <sub_title>Application Site Reaction</sub_title>
                <counts group_id="E1" events="6" subjects_affected="6" subjects_at_risk="38"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="23"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Any Infections and Infestations</sub_title>
                <counts group_id="E1" events="16" subjects_affected="12" subjects_at_risk="38"/>
                <counts group_id="E2" events="11" subjects_affected="7" subjects_at_risk="23"/>
              </event>
              <event>
                <sub_title>Application Site Pustules</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="38"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="23"/>
              </event>
              <event>
                <sub_title>Bronchitis Bacterial</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="38"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="23"/>
              </event>
              <event>
                <sub_title>Nasopharyngitis</sub_title>
                <counts group_id="E1" events="7" subjects_affected="6" subjects_at_risk="38"/>
                <counts group_id="E2" events="6" subjects_affected="5" subjects_at_risk="23"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Investigations</title>
            <event_list>
              <event>
                <sub_title>Any Investigations</sub_title>
                <counts group_id="E1" events="5" subjects_affected="2" subjects_at_risk="38"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="23"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Any Musculoskeletal and Connective Tissue Disorders</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="38"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="23"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Headache</sub_title>
                <counts group_id="E1" events="9" subjects_affected="6" subjects_at_risk="38"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="23"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Any Skin and Subcutaneous Tissue Disorders</sub_title>
                <counts group_id="E1" events="13" subjects_affected="7" subjects_at_risk="38"/>
                <counts group_id="E2" events="6" subjects_affected="5" subjects_at_risk="23"/>
              </event>
              <event>
                <sub_title>Erythema</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="38"/>
                <counts group_id="E2" events="3" subjects_affected="2" subjects_at_risk="23"/>
              </event>
              <event>
                <sub_title>Pruritus</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="38"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="23"/>
              </event>
              <event>
                <sub_title>Rosacea</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="38"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="23"/>
              </event>
              <event>
                <sub_title>Skin Burning Sensation</sub_title>
                <counts group_id="E1" events="3" subjects_affected="2" subjects_at_risk="38"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="23"/>
              </event>
              <event>
                <sub_title>Skin Reaction</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="38"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="23"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <limitations_and_caveats>Phase 2 pilot study so sample size was small.</limitations_and_caveats>
    <point_of_contact>
      <name_or_title>Katherine D'Angelo</name_or_title>
      <organization>Dr. Reddy's Laboratories</organization>
      <phone>609-282-1400</phone>
      <email>kdangelo@drreddys.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

